Amrani F C, Cheaw S L, Chevalier B, Paolaggi F, Jouquey S, Hamon G, Swynghedauw B
U127-INSERM, Hopital Lariboisière, Paris, France.
J Cardiovasc Pharmacol. 1994 Jan;23(1):155-65. doi: 10.1097/00005344-199401000-00022.
The effects of trandolapril, a converting enzyme inhibitor (CEI), on left ventricular (LV) diastolic stiffness and coronary vascular resistance (CVR), were studied with an isolated heart preparation in 15-month-old spontaneously hypertensive rats (SHR). The hypertensive animals were treated for 3 months with trandolapril (0.3 mg/kg/day) (SHRT), and compared with untreated age-matched Wistar-Kyoto rats (WKY) and SHR. Trandolapril treatment resulted in 15% diminution in blood pressure (BP). In contrast, it completely normalized left ventricular (LV) weight. Untreated SHR, as compared with WKY, had a dilated LV and increased diastolic tissue stiffness. Trandolapril had no effect on either chamber or tissue stiffness. Five-minute anoxia resulted in the same dramatic increase in chamber stiffness in every experimental group. During anoxia, as during normoxia, tissue stiffness was still greater in SHR than in WKY. A major effect of CEI was to normalize the tissue stiffness of SHR under anoxia. Coronary vascular resistance (CVR) was increased in SHR as compared with WKY. Trandolapril improves CVR and significantly shifts the coronary pressure flow curve to the dilatory side. Both collagen concentration (approximately 2 mg/g) and the content in slow V3 myosin isoform, used as biologic markers of cardiac senescence, were the same in the three experimental groups, but higher than in young hearts. Trandolapril had no effect on these parameters. In semisenescent SHR, despite having rather slight effect on arterial pressure, trandolapril completely normalized LV weight. In addition, collagen content and its physiologic counterpart, tissue stiffness, were unaffected by 3-month treatment with trandolapril. Nevertheless, the anoxia-induced increase in LV tissue stiffness was improved by trandolapril in parallel with reduction in LV hypertrophy (LVH).
在15月龄自发性高血压大鼠(SHR)的离体心脏标本上,研究了转化酶抑制剂(CEI)群多普利对左心室(LV)舒张硬度和冠状血管阻力(CVR)的影响。用群多普利(0.3mg/kg/天)对高血压动物进行3个月治疗(SHRT),并与未治疗的年龄匹配的Wistar-Kyoto大鼠(WKY)和SHR进行比较。群多普利治疗使血压(BP)降低了15%。相比之下,它使左心室(LV)重量完全恢复正常。与WKY相比,未治疗的SHR左心室扩张,舒张期组织硬度增加。群多普利对心室或组织硬度均无影响。五分钟缺氧导致每个实验组的心室硬度都出现相同程度的显著增加。在缺氧期间,与常氧期间一样,SHR的组织硬度仍高于WKY。CEI的一个主要作用是使SHR在缺氧状态下的组织硬度恢复正常。与WKY相比,SHR的冠状血管阻力(CVR)增加。群多普利改善CVR,并使冠状压力-流量曲线明显向扩张侧移动。用作心脏衰老生物学标志物的胶原浓度(约2mg/g)和慢V3肌球蛋白同工型含量在三个实验组中相同,但高于年轻心脏。群多普利对这些参数没有影响。在半衰老的SHR中,尽管群多普利对动脉压影响较小,但它使左心室重量完全恢复正常。此外,胶原含量及其生理对应物组织硬度不受群多普利3个月治疗的影响。然而,群多普利在减轻左心室肥厚(LVH)的同时,改善了缺氧诱导的左心室组织硬度增加。